Tirzepatide

Investigated uses

• Type 2 diabetes, chronic weight management and obstructive sleep apnea in label-defined populations.

Mechanism and hypotheses

• Tirzepatide is a dual GIP- and GLP-1-receptor agonist that improves glucose-dependent insulin secretion and reduces energy intake in the approved formulations.
• Hypothesized: The relative contribution of GIP and GLP-1 signaling to individual outcomes does not establish equivalence of a research vial or “Double Agonist” product.

Human evidence

• SURMOUNT-1 randomized 2,539 adults for 72 weeks to 5, 10 or 15 mg weekly or placebo and found dose-dependent, substantial weight reduction. Limitations: Results apply to trial-manufactured tirzepatide with protocolized escalation and monitoring.
• Two SURMOUNT-OSA trials enrolled 469 adults with obesity and moderate-to-severe obstructive sleep apnea; tirzepatide reduced apnea–hypopnea index and body weight versus placebo over 52 weeks. Limitations: Participants met specific OSA criteria; treatment was protocolized and product quality controlled.

Safety highlights

• Nausea, diarrhea, vomiting, constipation, abdominal symptoms and injection-site reactions are among common labeled adverse reactions.
• Label risks include pancreatitis, gallbladder disease, dehydration-associated kidney injury, severe gastrointestinal reactions and hypoglycemia with insulin/secretagogues.

Regulatory context

Mounjaro and Zepbound are FDA-approved product-specific formulations; a research vial is not either approved presentation.